Description: Bioventix PLC is a United Kingdom-based biotechnology company. The principal activity of the Company is the development and supply of antibodies. The Company specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing. The Company's non-vitamin D business consists of antibodies, NT proBNP (heart failure), testosterone, Free Triiodothyronine (FT3) (thyroid hormone), estradiol, and various drugs, such as tetrahydrocannabinol (THC)/cannabis, and progesterone. The Company offers products for indications, such as thyroid, fertility, oncology, cardiac, vitamin D, drug of abuse, infectious disease and miscellaneous. Its sheep hybridoma technology produces cell lines that secrete SMAs. The Company offers a panel of SMAs to 25-OH D and has various 25-OH D2 and 25-OH D3 specific antibodies. It sells its products through direct sales and through distributors.
Home Page: www.bioventix.com
BVXP Technical Analysis
27–28 Eastcastle Street
London,
W1W 8DH
United Kingdom
Phone:
44 12 5272 8001
Officers
| Name | Title |
|---|---|
| Mr. Peter John Harrison MA | CEO & Director |
| Mr. Bruce Edward Heath Hiscock | CFO & Director |
Exchange: LSE
Country: UK : United Kingdom
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 24.2131 |
|---|---|
| Trailing PE: | 28.7671 |
| Price-to-Book MRQ: | 16.2611 |
| Price-to-Sales TTM: | 16.4024 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 12 |